Taking advantage of antisense oligodeoxynucleotides (AS-ODNs) to downregulate BCL-2 can partially sensitize bladder cancers to cisplatin and radiotherapy [84,85]. This evidence concerns the gene BCL2 and urinary bladder cancer.